

The Evolution of Anti-microbial/biotic Stewardship

0000001 27, 2022

George D. Rodriguez, PharmD, BCIDP Director, Quality & Patient Safety, Regulatory Affairs NewYork-Presbyterian Queens Cell: 718-640-7851 Email: Gdr9005@nyp.org


Disclosures

• None

Objectives

- Discuss timeline of Antibiotic Stewardship
- Identify current best practices
- Interpret new and revised requirements from The Joint Commission
- Recognize future direction and opportunities in Antibiotic Stewardship

Antimicrobial/biotic Stewardship Program Timeline^{*}



*And so much more in between from many organizations and researchers

June 26, 1945



Early Evidence of Antibiotic Stewardship

PENICILLIN'S FINDER ASSAYS ITS FUTURE

Sir Alexander Fleming Says Improved Dosage Method Is Needed to Extend Use

Sir Alexander Fleming, discoverer of penicillin, said last night that a better method of administering the drug than by injection every two or three hours as at present was needed to extend its use. The British scientist warned, however, in speaking at a dinner in his honor in the Hotel Waldorf-Astoria, that administration by mouth would lead to "self-medication and all its abuses."

Self-Medication Decried

"But the public will demand a preparation which can be taken by mouth, and doubtless they will get it. Then will begin an era of self-medication with penicillin, with all its abuses. The wrong source of infection will be treated, but this does not matter so much so long as large doses are not taken. It will only mean disappointment to one individual.

"The greatest possibility of evil in self-medication is the use of toosmall doses, so that, instead of clearing up the infection, the microbes are educated to resist penicillin and a host of penicillin-fast organisms is bred out which can be passed on to other individuals and perhaps from there to others until they reach someone who gets a septicemia or a pneumonia which penicillin cannot save.

"In such a case the thoughtless person playing with penicillin treatment is morally responsible for the death of the man who finally succumbs to infection with the penicillin-resistant organism. Ihope this evil can be averted."

Ehe New York Eimes

Published: June 26, 1945 Copyright © The New York Times

6

Early Evidence of Antibiotic Stewardship

Self-Medication Decried

"But the public will demand a preparation which can be taken by mouth, and doubtless they will get it. Then will begin an era of self-medication with penicillin, with all its abuses. The wrong source of infection will be treated, but this does not matter so much so long as large doses are not taken. It will only mean disappointment to one individual.

"The greatest possibility of evil in self-medication is the use of too-

of

e mipeni-

i-fast in be i and

until ts a

"I hope this [collateral of inappropriate antibiotic use] evil can be averted." -Sir Alexander Fleming, 1945

> erer of penicillin, said last night that a better method of administering the drug than by injection every two or three hours as at present was needed to extend its use. The British scientist warned, however, in speaking at a dinner in his honor in the Hotel Waldorf-Astoria, that administration by mouth would lead to "self-medication and all its abuses."

PENICILLIN'S FINDER

ASSAYS ITS FUTURE

septicemia or a pneumonia which penicillin cannot save.

"In such a case the thoughtless person playing with penicillin treatment is morally responsible for the death of the man who finally succumbs to infection with the penicillin-resistant organism. Ihope this evil can be averted."

The New York Times

Published: June 26, 1945 Copyright © The New York Times

52 Years Later

Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the Prevention of Antimicrobial Resistance in Hospitals

David M. Shlaes, Dale N. Gerding, Joseph F. John, Jr., William A. Craig, Donald L. Bornstein, Robert A. Duncan, Mark R. Eckman, William E. Farrer, William H. Greene, Victor Lorian, Stuart Levy, John E. McGowan, Jr., Sindy M. Paul, Joel Ruskin, Fred C. Tenover, and Chatrchai Watanakunakorn

From Wyeth-Averst Research (Dr. Shlaes), Pearl River, New York; Veterans' Affairs Lakeside Medical Center (Dr. Gerding), Chicago, Illinois; UMDNJ-Robert Wood Johnson Medical School (Dr. John), New Brunswick, New Jersey; William S. Middleton Memorial Veterans' Hospital (Dr. Craig), Madison, Wisconsin; SUNY Health Science Center (Dr. Bornstein), Syracuse, New York; Lahey Clinic (Dr. Duncan), Burlington, Massachusetts; Duluth Clinic Limited (Dr. Eckman), Duluth, Minnesota; St. Elizabeth Hospital (Dr. Farrer), Elizabeth, New Jersey; University Hospital (Dr. Greene), State University of New York, Stony Brook, New York; Bronx-Lebanon Hospital Center (Dr. Lorian), Bronx, New York; Tufts University School of Medicine (Dr. Levy), Boston, Massachusetts; Grady Memorial Hospital (Dr. McGowan), Atlanta, Georgia; New Jersey Department of Health (Dr. Paul), Trenton, New Jersey; Kaiser Permanente Medical Center (Dr. Ruskin), Los Angeles, California; Centers for Disease Control and Prevention (Dr. Tenover), Atlanta, Georgia; and St. Elizabeth Hospital Medical Center (Dr. Watanakunakorn), Youngstown, Ohio

Antimicrobial resistance results in increased morbidity, mortality, and costs of health care. Prevention of the emergence of resistance and the dissemination of resistant microorganisms will reduce these adverse effects and their attendant costs. Appropriate antimicrobial stewardship that includes optimal selection, dose, and duration of treatment, as well as control of antibiotic use, will prevent or slow the emergence of resistance among microorganisms. A comprehensively applied infection control program will interdict the dissemination of resistant strains.

Vision




Figure 1. Flow of information, recommendations, and policies for the development of hospital policies to prevent the emergence and dissemination of resistance. Expert committees of the hospital, taking

SHEA/IDSA 2007

Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship

Timothy H. Dellit,¹ Robert C. Owens,² John E. McGowan, Jr.,³ Dale N. Gerding,⁴ Robert A. Weinstein,⁵ John P. Burke,⁶ W. Charles Huskins,⁷ David L. Paterson,⁸ Neil O. Fishman,⁹ Christopher F. Carpenter,¹⁰ P. J. Brennan,⁹ Marianne Billeter,¹¹ and Thomas M. Hooton¹²

¹Harborview Medical Center and the University of Washington, Seattle; ²Maine Medical Center, Portland; ³Emory University, Atlanta, Georgia; ⁴Hines Veterans Affairs Hospital and Loyola University Stritch School of Medicine, Hines, and ⁵Stroger (Cook County) Hospital and Rush University Medical Center, Chicago, Illinois; ⁶University of Utah, Salt Lake City; ⁷Mayo Clinic College of Medicine, Rochester, Minnesota; ⁸University of Pittsburgh Medical Center, Pittsburgh, and ⁹University of Pennsylvania, Philadelphia, Pennsylvania; ¹⁰William Beaumont Hospital, Royal Oak, Michigan; ¹¹Ochsner Health System, New Orleans, Louisiana; and ¹²University of Miami, Miami, Florida

SHEA/IDSA 2016

Clinical Infectious Diseases

IDSA GUIDELINE



Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America

Tamar F. Barlam,^{1,a} Sara E. Cosgrove,^{2,a} Lilian M. Abbo,³ Conan MacDougall,⁴ Audrey N. Schuetz,⁵ Edward J. Septimus,⁶ Arjun Srinivasan,⁷ Timothy H. Dellit,⁸ Yngve T. Falck-Ytter,⁹ Neil O. Fishman,¹⁰ Cindy W. Hamilton,¹¹ Timothy C. Jenkins,¹² Pamela A. Lipsett,¹³ Preeti N. Malani,¹⁴ Larissa S. May,¹⁵ Gregory J. Moran,¹⁶ Melinda M. Neuhauser,¹⁷ Jason G. Newland,¹⁸ Christopher A. Ohl,¹⁹ Matthew H. Samore,²⁰ Susan K. Seo,²¹ and Kavita K. Trivedi²²

¹Section of Infectious Diseases, Boston University School of Medicine, Boston, Massachusetts; ²Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland; ³Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, Florida; ⁴Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco; ⁵Department of Medicine, Weill Cornell Medical Center/New York–Presbyterian Hospital, New York, New York; ⁶Department of Internal Medicine, Texas A&M Health Science Center College of Medicine, Houston; ⁷Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia; ⁸Division of Allergy and Infectious Diseases, University of Washington School of Medicine, Seattle; ⁹Department of Medicine, Case Western Reserve University and Veterans Affairs Medical Center, Cleveland, Ohio; ¹⁰Department of Medicine, University of Pennsylvania Health System, Philadelphia; ¹¹Hamilton House, Virginia Beach, Virginia; ¹²Division of Infectious Diseases, Denver Health, Denver, Colorado; ¹³Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University Schools of Medicine and Nursing, Baltimore, Maryland; ¹⁴Division of Infectious Diseases, University of California, Los Angeles Medical Center, Sylmar; ¹⁷Department of Veterans Affairs, Hines, Illinois; ¹⁸Department of Emergency Medicine, David Geffen School of Medicine, University of California, Los Angeles Medical Center, Sylmar; ¹⁷Department of Veterans Affairs, Hines, Illinois; ¹⁸Department of Veterans Affairs and University of Utah, Salt Lake City; ²¹Infectious Diseases, Memorial Sloan Kettering Cancer Center, New York; New York; and ²²Trivedi Consults, LLC, Berkeley, California

The Joint Commission Proposed Standard for Antimicrobial Stewardship Effective January 1, 2017



Prepublication Requirements

The Joint Commission has approved the following revisions for prepublication. While revised requirements are published in the semiannual updates to the print manuals (as well as in the online E-dition[®]), accredited organizations and paid subscribers can also view them in the monthly periodical *The Joint Commission Perspectives*[®]. To begin your subscription, call 877-223-6866 or visit http://www.jcrinc.com.



New Antimicrobial Stewardship Standard

APPLICABLE TO HOSPITALS AND CRITICAL ACCESS HOSPITALS

Effective January 1, 2017

Medication Management (MM)

Standard MM.09.01.01

The [critical access] hospital has an antimicrobial stewardship program based on current scientific literature.

Elements of Performance for MM.09.01.01

 Leaders establish antimicrobial stewardship as an organizational priority. (See also LD.01.03.01, EP 5) Note: Examples of leadership commitment to an antimi-

crobial stewardship program are as follows:

- Accountability documents
- Budget plans
- Infection prevention plans
- Performance improvement plans
- Strategic plans
- Using the electronic health record to collect antimicrobial stewardship data
- The [critical access] hospital educates staff and licensed independent practitioners involved in antimicrobial ordering, dispensing, administration, and monitoring about antimicrobial resistance and antimicrobial stewardship practices. Education occurs upon hire or granting of initial privileges and periodically thereafter, based on organizational need.
- The [critical access] hospital educates patients, and their families as needed, regarding the appropriate use of antimicrobial medications, including antibiotics. (For more information on patient education, refer to Standard PC.02.03.01)

Note: An example of an educational tool that can be used for patients and families includes the Centers for Disease Control and Prevention's Get Smart document, "Viruses or Bacteria—What's got you sick? at <u>http://www.cdc.gov/</u> getsmart/community/downloads/getsmart-heart.pdf.

- The [critical access] hospital has an antimicrobial stewardship multidisciplinary team that includes the following members, when available in the setting:
 - Infectious disease physician
 - Infection preventionist(s)
 - Pharmacist(s)
 - Practitioner

Note 1: Part-time or consultant staff are acceptable as members of the antimicrobial stewardship multidisciplinary team.

Note 2: Telehealth staff are acceptable as members of the antimicrobial stewardship multidisciplinary team.

- D The [critical access] hospital's antimicrobial stewardship program includes the following core elements:
 - Leadership commitment: Dedicating necessary human, financial, and information technology resources.
 - Accountability: Appointing a single leader responsible for program outcomes. Experience with successful programs shows that a physician leader is effective.
 - Drug expertise: Appointing a single pharmacist leader responsible for working to improve antibiotic use.
 - Action: Implementing recommended actions, such as systemic evaluation of ongoing treatment need, after a set period of initial treatment (for example, "antibiotic time out" after 48 hours).
 - Tracking: Monitoring the antimicrobial stewardship program, which may include information on antibiotic prescribing and resistance patterns.

Key: A indicates scoring category A; C indicates scoring category C; (1) indicates that documentation is required; (1) indicates Measure of Success is needed; A indicates an Immediate Threat to Health or Safety; (1) indicates situational decision rules apply; (2) indicates direct impact requirements apply; (1) indicates and identified risk area

Copyright 2016 The Joint Commission

Leadership

- Recognized and supported by senior leadership for its need and potential
- Financial support
- Accountability
- Inf Prev/PI Plans
- Electronic health record

Employee Education

 Education provided to all employees involved with antibiotic use

- Ordering, dispensing, administration, monitoring

- Frequency: Upon hire and annually thereafter
- Content: Not specified

Patient/Family Education

- Originally designed to educate patient and family members regarding antimicrobials
- Removed from standard due to feasibility

Multidisciplinary Team

- Team includes the following members
 - Infectious Disease Physician
 - Infection Preventionist(s)
 - Pharmacist(s)
 - Practitioner

*Part-time, consultant, and/or telehealth staff are acceptable

Core Elements

- Leadership commitment
- Accountability (program lead)
- Drug expertise (pharmacist lead)
- Action (Processes)
- Tracking (Outcomes)
- Reporting
- Education

Organization-approved Protocols

- Antibiotic Formulary Restriction
- Pre-authorization protocol
- Surgical Prophylaxis
- Plan for IV to PO Antibiotic Conversion
- Disease specific protocols
- Others

Collect, Analyze, and Report Data

- Process measures
- Outcomes measures
- Analyze data to monitor trends and identify areas of opportunity
- Report data to necessary audiences

Performance Improvement

- The hospital takes action on improvement opportunities identified
 - Education
 - Modify/add protocols
 - Non-specific

Best Practices

- Leadership
 - Financial, prioritize, culture
- Employee education
 - Annual hospital training, orientation, departmentspecific, incorporate into daily processes
- Multidisciplinary Team
 - Collaboration, communication
 - Strategize meetings




Best Practices

- Core Elements/Collect, Analyze, Report Data
 - Trend interventions by type, location
 - Trend DOTs/1000 Pt Days using software/EMR
 - Submit data to NHSN and trend SAAR
 - Trend resistance data using Antibiogram
 - Other data as it pertains to PI project
 - Report at meetings, unit level
- Protocols
 - Incorporate antibiogram, evidence
 - Operationalize within EMR/pathways
 - Eliminate those not used

Best Practices

- Performance Improvement
 - Antibiotic use/resistance
 - Disease-specific approach
 - Rapid Diagnostics
 - New Treatment
 - Covid-19
 - Research

APIC Resources



Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.

Misuse and overuse of antimicrobials is one of the world's most pressing public health problems. Infectious organisms adapt to the antimicrobials designed to kill them, making the drugs ineffective. People infected with antimicrobial-resistant organisms are more likely to have longer, more expensive hospital stays, and may be more likely to die as a result of an infection. This page contains antimicrobial stewardship resources and education for both healthcare professionals and consumers.

For Healthcare Professionals For

Is For Consumers

The following links are APIC resources on antimicrobial stewardship for healthcare professionals.

Statements and position papers


- NEW! Antimicrobial stewardship and infection prevention Leveraging the synergy: A position paper update, April 2018
- APIC statement in support of the National Action Plan for Combating Antibiotic-Resistant Bacteria, March 27, 2015
- Antimicrobial stewardship: A collaborative partnership between infection preventionists and health care epidemiologists—APIC and the Society for Healthcare Epidemiology of America, March 2012

Implementation guides and tools

- Guide to Preventing Clostridium difficile Infections (2013)—Implementation Guide
- Guide to the Elimination of Methicillin-Resistant Staphylococcus aureus (MRSA) Transmission in Hospital Settings, 2nd Edition (2010)—Implementation Guide
- Guide to the Elimination of Methicillin-Resistant Staphylococcus aureus (MRSA) in the Long-Term Care Facility (2009)—Implementation Guide
- Guide to the Elimination of Multidrug-resistant Acinetobacter baumannii Transmission in Healthcare Settings (2010)—Implementation Guide
- APIC Text (subscription required)
 - Chapter 26, "Antimicrobials and Resistance"

https://apic.org/resources/topic-specific-infection-prevention/antimicrobial-stewardship/

Antimicrobial/biotic Stewardship Program Timeline^{*}



*And so much more in between from many organizations and researchers

6 years later...what have we learned?

R³ **Report** Requirement, Rationale, Reference

A complimentary publication of The Joint Commission

Issue 35, June 20, 2022

Published for Joint Commission-accredited organizations and interested health care professionals, *R3 Report* provides the rationale and references that The Joint Commission employs in the development of new requirements. While the standards manuals also may provide a rationale, *R3 Report* goes into more depth, providing a rationale statement for each element of performance (EP). The references provide the evidence that supports the requirement. *R3 Report* may be reproduced if credited to The Joint Commission. Sign up for <u>email</u> delivery.

New and Revised Requirements for Antibiotic Stewardship

Effective January 1, 2023, new and revised antibiotic stewardship requirements will apply to all Joint Commission– accredited hospitals and critical access hospitals. The 12 elements of performance (EPs) are included in the "Medication Management" (MM) chapter (Standard MM.09.01.01) and expand upon the current expectations for antibiotic stewardship programs in the hospital setting.

EP 10 (new)

 The hospital allocates financial resources for staffing and <u>information technology</u> to support the antibiotic program

EP 11 (revised)

- The governing body appoints a physician and/or pharmacist who is qualified through education, training, or experience in infectious diseases and/or antibiotic stewardship as the leader(s) of the antibiotic stewardship program
- Appointment based on recommendations of medical staff leadership and pharmacy leadership

EP 12 (revised)

- Leaders(s) responsible for
 - Developing/implementing program
 - Documenting activities
 - Communicating and collaborating with medical staff, <u>nursing leadership</u>, pharmacy leadership, <u>infection</u> <u>prevention and control, and QAPI programs</u> on antibiotic issues
 - Provide <u>competency-based training and education</u> <u>for staff</u>, including medical staff, on the <u>practical</u> <u>applications of antibiotic stewardship guidelines</u>, <u>policies, and procedures</u>

EP 13 (revised)

• Multidisciplinary committee

May include <u>medical staff</u>, pharmacy services,
 <u>IPC, nursing</u>, microbiology, <u>IT, QAPI</u>

EP 14 (revised)

- The antibiotic stewardship program
 <u>demonstrates coordination</u> among all
 components of the hospital responsible for
 use and resistance
 - IPC
 - QAPI
 - Medical staff
 - Nursing services
 - Pharmacy services

EP 15 (revised)

The antibiotic stewardship program
 <u>documents the evidence-based use</u> of
 antibiotics in all departments and services of
 the hospital

EP 16 (new)

- The antibiotic stewardship program monitors the hospital's antibiotic use by analyzing
 - Days of Therapy (DOT) per 1000 days present or patient days <u>OR</u>
 - Reporting antibiotic use data to the National Healthcare Safety Network's Antibiotic Use Option of the AU/AR Module

EP 17 (new)

- The antibiotic stewardship program implements one or both of the following
 - Preauthorization for specific antibiotics that includes review and approval process
 - Prospective review and feedback regarding antibiotic prescribing practices, <u>including the</u> <u>treatment of positive blood cultures</u>, by a member of the antibiotic stewardship program

EP 18 (new)

- The antibiotic stewardship program implements at least two evidence-based guidelines to <u>improve antibiotic use</u> for the most common indications
 - Community-acquired pneumonia
 - Urinary Tract Infection
 - Skin and Soft Tissue Infection
 - Clostridioides difficile infection
 - Others

EP 19 (new)

- The antibiotic stewardship program <u>evaluates</u> <u>adherence</u> (including selection and duration, where applicable) to at least one of the guidelines implemented
 - Group level (department, unit, clinician subgroup) or Individual prescriber level
 - Adherence data may be obtained for a sample of patients from relevant areas using EMR or conducting chart reviews

EP 20 (revised)

- The antibiotic stewardship program collects, analyzes, reports data to <u>hospital leadership</u> <u>and prescribers</u>
 - Resistance patterns
 - Prescribing patterns
 - Evaluations of activities


EP 21 (revised)

• The <u>hospital takes action</u> on improvement opportunities identified by the antibiotic stewardship program

Future Direction

- New and revised standards designed to elevate us to even higher standards for patient care and safety
- Data driven
- Structure
- Accountability
- Collaboration
- Communication
- Culture
- Creativity and Bespoke approach

Standard LD.04.03.08: Reducing health care disparities for the hospital's patients is a quality and safety priority




Home > Standards > Prepublication Standards > New and Revised Requirements to Reduce Health Care Dispar

New and Revised Requirements to Reduce Health Care Disparities

Effective January 1, 2023, new and revised requirements to reduce health care disparities will apply to Join Commission–accredited ambulatory health care organizations, behavioral health and human services organizations, critical access hospitals, and hospitals.

A new standard in the Leadership (LD) chapter with 6 new elements of performance (EPs) has been developed to address health care disparities as a quality and safety priority. Standard LD.04.03.08 will apply to the following loint Commission-accredited organizations:

https://www.jointcommission.org/standards/prepublication-standards/new-and-revised-requirements-to-reduce-health-care-disparities/linear-dispari





EQUALITY EQUITY
http://www.socialventurepartners.org/wp-content/uploads/2018/01/Problem-with-Equity-vs-Equality-Graphic.pdf

What Can I Do Tomorrow?

- Designate antibiotic stewardship as a standing agenda item at your IPC meeting with official report out
- Consider incorporating antibiotic stewardship into your orientation education
- Collaborate and begin reporting AU data to NSHN
- Provide list of + blood cultures to antibiotic stewardship team
- Breakdown any silo that may exist between IPC and antibiotic stewardship (think: Quality and Patient Safety)
 - Learn from each other!
- Consider collaborating on Performance Improvement initiatives
- Incorporate health care disparities when analyzing data to further optimize the safety and quality of care you provide everyday



The Evolution of Anti-microbial/biotic Stewardship

October 27, 2022

George D. Rodriguez, PharmD, BCIDP Director, Quality & Patient Safety, Regulatory Affairs NewYork-Presbyterian Queens Cell: 718-640-7851 Email: Gdr9005@nyp.org